Abstracts

2023

SITC

A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combination with a PD1-41BB armoring and enhancement costimulatory switch receptor
Dolores J Schendel, Giulia Longinotti, Mario Catarinella, Melanie Salvermoser, Julia Bittmann, Kirsty Crame, Kathrin Davari and Selwyn Ho

Poster

ESMO

Mitigation of Tumor Microenvironment-Mediated Immunosuppression Using a PD1-41BB Switch Protein with Optimal Affinity TCRs for First-In-Class, 3rd Generation TCR-T Therapies
Kirsty Crame, Giulia Longinotti, Mario Catarinella, Petra U Prinz, Stefanie Tippmer, Kathrin Mutze, Andrea Coluccio, Melanie Salvermoser, Julia Bittmann, Maja Buerdek, Barbara Loesch, Christiane Geiger, Kathrin Davari, and Dolores J Schendel

Poster

CAR-TCR Summit Boston

Improving TCR-T Therapeutic Persistence and Efficacy with Switch Receptors; Dolores Schendel

Presentation

Immuno-Oncology Summit Europe

PD1-41BB Switch Receptor Technology Added to TCR-Ts Further Enhances Antitumor Activity in vitro and in vivo compared to TCR alone Barbara Lösch

Presentation

 

CIMT

Expitope 3.0 An Advanced in silico Webtool Empowered with Machine Learning for Enhanced pHLA Epitope Prediction and Safety Assessment Simone Thomas, Martin Sebastian Karg, Andrea Coluccio, Barbara Lösch, Dolores J Schendel, Dmitrij Frishman

Presentation

Poster

EBMT

First-in-Human Study of MDG1011, a TCR-T Cell Therapy directed against HLA-A*02:01-Restricted PRAME, for High-Risk Myeloid and Lymphoid Neoplasms (CD-TCR-001) Simone Thomas, Martin Wermke, Vladan Vucinic, Eva Wagner-Drouet, Andreas
Mackensen, Robert Zeiser, Gesine Bug, Michael Schmitt, Petra U. Prinz, Dolores J. Schendel, Kai Pinkernell, René Goedkoop

Poster

AACR

T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors Andrea Coluccio, Stefanie Tippmer, Kathrin Mutze, Petra U Prinz, Maja Buerdek, Barbara Loesch, Kathrin Davari, Giulia Longinotti, Dolores J Schendel

Poster

TCR-based Therapies for Solid Tumors

Case Study Spotlight: Introducing Innovations at Each Step of TCR-T Therapy Development; Dolores Schendel

Presentation

CAR TCR Europe

Transitioning from a multi modular system to a single automated device for TCR T production; Dolores Schendel

Presentation

2022

Cell UK

High Fidelity Production of TCR-T Cells from Elderly Hematologically-Challenged Patients With Blood Cancers; Dolores Schendel

Presentation

CHI Immuno-Oncology Summit

TCR-Ts overcoming TME hurdles by switching immunosuppression to T cell activation with integrated Switch Receptor Technology; Dolores Schendel

Presentation

Immuno UK

Immune monitoring tools and their application; Petra Prinz

Presentation

CAR-TCR Summit

Combined Molecular & Cellular Tools are Required to Assess Safety of TCR-T Immunotherapies; Tristan Holland

Presentation

Next Generation CAR-TCR Summit

Identify Peptide Targets for TCR-Ts Derived from Non-Coding RNA Sequences; Justyna Ogonek

Presentation

2021

ESMO Immuno-Oncology Congress

The inducible Medigene T cell receptor ( iM TCR) controls cytotoxicity of tumor specific TCR modified T cells with improved avidity through control of TCR surface expression, Andreas Acs, Adriana Turqueti Neves, Justyna Ogonek, Barbara Loesch, Dolores J. Schendel, Slavoljub Milosevic

Poster

Cellular Immunotherapies for Solid Tumors Summit

Empowering TCR-Ts to infiltrate, proliferate and control solid tumors in a hostile tumor microenvironment, Dolores Schendel

Presentation

SITC 2021

Targeting a novel shared tumor-specific antigen with T cell receptor transduced T cells for the treatment of ovarian cancer Justyna Ogonek, Tiziana Franceschetti, Andreas Acs, Alexander Schmidt, Alexandra Kuhlenkamp, Krystel Vincent, Claude Perreault, Barbara Loesch, Adriana Turqueti Neves, Slavoljub Milosevic, Dolores J. Schendel and Daniel Sommermeyer

Poster

Video presentation

Neoantigen Based Therapies Summit

Dark Matter Antigens: Exploration with Molecular and Cellular Tools; Dolores Schendel

Presentation

ESMO

T cells transgenic for a highly potent PRAME-specific TCR and a chimeric PD1-41BB co-stimulatory receptor represent a promising approach for the treatment of solid tumors; Maja Bürdek, Ina Fetzer, Nadja Sailer, Melanie Salvermoser, Doris Brechtefeld, Kathrin Mutze, Silke Raffegerst, Monika Braun, René Goedkoop, Susanne Wilde, Daniel Sommermeyer

Poster

TCR-based Therapies Summit

T cells equipped with both a highly potent PRAME-specific T cell receptor and a chimeric PD1-41BB co-stimulatory receptor show superior in vitro and in vivo tumor reactivity; Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Doris Brechtefeld, Maja Bürdek, Kathrin Mutze, Monika Braun, Dolores J. Schendel, Susanne Wilde, Daniel Sommermeyer

Poster

Helping TCR-Ts Meet the Challenges of the TME; Dolores J. Schendel

CIMT 2021

Inducible Medigene T cell receptor (iM-TCR): Controlled cytotoxicity of tumor-specific TCR-modified T cells with improved avidity through control of TCR surface expression; Adriana Turqueti Neves, Andreas Acs, Justyna Ogonek, Barbara Loesch,  Dolores J. Schendel, Slavoljub Milosevic

eTalk

T cells expressing a highly potent PRAME-specific T cell receptor equipped with a PD1-41BB switch receptor show a favorable preclinical safety profile, strong anti-tumor reactivity and superior fitness; Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Doris Brechtefeld, Maja Bürdek, Kathrin Mutze, Monika Braun, Susanne Wilde, Daniel Sommermeyer

eTalk

Tumor specific antigens derived from non-mutated non-coding regions of the genome can be targeted by T-cell receptor-transgenic T cells; Anna Schleicher, Alexandra Kuhlenkamp, Qingchuan Zhao, Krystel Vincent, Claude Perreault, Slavoljub Milosevic, Tiziana Franceschetti, and Daniel Sommermeyer

eTalk

AACR 2021

Combining a PRAME-specific TCR showing potent in vitro and in vivo anti-tumor reactivity and a favorable preclinical safety profile with a PD1-41BB switch receptor results in highly efficient T cells; Ina Fetzer, Nadja Sailer, Melanie Salvermoser, Manon Weis, Christian Krendl, Maja Bürdek, Doris Brechtefeld, Isabella Rampp, Julian Rydzek-Wiesner, Monika Braun, Christian Ellinger, Christiane Geiger, Daniel Sommermeyer, Susanne Wilde

Poster [nomenclature adapted]

Targetable immunogenic tumor specific antigens can be identified in non-coding regions of the genome; Franceschetti T, Zhao Q, Vincent K, Perreault C, Milosevic S and Sommermeyer D

Poster

TCT 2021

Long term follow up of a ‘fast-DC’ immunotherapy against WT-1 and PRAME as a post-remission strategy for AML; Yngvar Fløsand, MD PhD, Mats Remberger, MD PhD, Iris Bigalke, MD, Dag Josefsen, MD PhD, Richard Addo, MD PhD, Dolores Schendel, PhD, Kai Pinkernell, MD, Gunnar Kvalheim, MD PhD

Poster

2020

ASH Annual Meeting and Exposition 2020

A WT-1 and PRAME “Fast-DC” Immunotherapy As a Potential Post-Remission Strategy for AML; Yngvar Floisand, MD, PhD, Iris Bigalke, MD, Dag Josefsen, MD, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Richard Addo, MD, PhD, Dolores J. Schendel, PhD, Kai Pinkernell, MD, Gunnar Kvalheim, MD, PhD

Presentation

PRAME mRNA Expression in AML/MDS and HLA Genotype Analysis: Impact on Population Coverage and Design of TCR-Based Immunotherapies; Richard Addo, MD, PhD, Kathrin Davari, PhD, Silke Raffegerst, PhD, Dolores Schendel, PhD, Kai Pinkernell, MD, Simone Thomas, MD

Presentation

SITC Annual Meeting 2020

Co-stimulation via PD1 41BB chimeric switch receptor enhances function of TCR T cells in an immune suppressive milieu and under chronic antigen stimulation; Melanie Salvermoser, Maria Gerget , Franziska Hasselmann, Elfriede Noessner, Christian Ellinger, Monika Braun, Dolores J. Schendel, Daniel Sommermeyer and Nadja Sailer

Poster

SITC Annual Meeting 2020

Consistent high-quality dendritic cell vaccines produced post-chemotherapy in patients with acute myeloid leukemia for use in a Phase I/II trial; Frauke Schnorfeil, Christiane Geiger, Iris Bigalke, Dag Josefsen, Yngvar Floisand, Gunnar Kvalheim,  Dolores J. Schendel, Anna Tafuri, Kai Pinkernell

Poster

SITC Annual Meeting 2020

Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy; Davari K, Holland T, Prassmayer L, Longinotti G, Ganley K, Pechilis LJ, Diaconu I, Nambiar PR, Magee MS, Schendel DJ, Sommermeyer D and Ellinger C

Poster

AACR Virtual Annual Meeting II 

The chimeric co-stimulatory receptor PD1-41BB enhances the function of T cell receptor (TCR)-modified T cells targeting solid tumors; Nadja Sailer, Melanie Salvermoser, Maria Gerget, Sarah Thome, Angelika J. Fischbeck, Svenja Ruehland, Luis F. Olguín-Contreras, Maja Buerdek, Christian Ellinger, Elfriede Noessner, Dolores J. Schendel, Patrik Kehler.

Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany, Helmholtz Zentrum München, Munich, Germany, Medigene AG, Planegg/Martinsried, Germany

Abstract

Poster

2019

ASH – American Society of Hematology Annual Meeting 2019, Orlando

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment; Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD, PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MD, MBA, Gunnar Kvalheim, MD, PhD, Dolores Schendel, Prof. and Anna Tafuri, MD

Abstract

Poster

SITC – Society for Immunotherapy of Cancer Annual Meeting 2019, National Harbor MD, USA

A. Bracher, S. Milosevic and D. Sommermeyer 2019. Targeting neoantigens with immunotherapy: Are we limited to pre-existing autologous neoantigen-specific T cells? SITC National Harbor, USA.

Poster

Congress of the European Hematology Association – EHA 2019, Amsterdam

Interim analysis of a WT-1 and PRAME ‘Fast-DC’ vaccine shows safety as active immunotherapy for the prevention of AML relapse; Yngvar Fløsand, Iris Bigalke, Dag Josefsen, Christiane Geiger, Kai Pinkernell, Gunnar Kvalheim

Abstract

Poster

CIMT – Annual Meeting of the Association for Cancer Immunotherapy 2019, Mainz, Germany

A safe and highly active NY-ESO-1/LAGE-1-specific TCR for adoptive T cell therapy of cancer; Longinotti G, Bürdek M, Weis M, Raffegerst S, Mösch A, Schendel DJ, Wehner C

Poster

AACR- American Association for Cancer Research Annual Meeting 2019, Atlanta

In vitro evaluation of TCR efficacy and toxicity using 3D spheroid models; Maja Buerdek, Kathrin Mutze, Kai Pinkernell, Dolores J. Schendel. Medigene Immunotherapies GmbH, Martinsried, Germany

Abstract

Poster

2018

ASH – American Society of Hematology Annual Meeting 2018, San Diego

Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use; Iris Bigalke, Judith Eckl, PhD, Guri Solum, MSc, Kirsti Hønnåshagen, Msc, Lisbeth Skoge, MSc, Yngvar Fløisand, MD, PhD, Dag Josefsen, MD, PhD, Stein Sæbøe-Larssen, PhD, Christiane Geiger, PhD, Dolores Schendel, PhD and Gunnar Kvalheim, MD, PhD.

Abstract

AACR – American Association for Cancer Research Annual Meeting 2018, Chicago, USA

Generation of clinical grade autologous TLR 7,8-polarized fast dendritic cell vaccines for active immunotherapy of patients with AML; Iris Bigalke, Lisbeth Johanne Skoge, Kirsti Hønnåshagen, Christiane Geiger, Gunnar Kvalheim, Dolores J. Schendel.

Abstract

Poster

2017

AACR – American Association for Cancer Research Annual Meeting 2017, Washington, D.C., USA

WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival; Iris Bigalke, Guri Solum, Dag Josefsen, Yngvar Fløisand, Kirsti Hønnåshagen, Lisbeth Skoge, Signe Spetalen, Stein Sæbøe-Larssen, Dolores J. Schendel, Gunnar Kvalheim.

Abstract

Isolation and characterization of a PRAME-specific TCR with high avidity, potent antitumor efficacy and a favorable preclinical safety profile; Manon Weis, Carina Wehner, Christian Ellinger, Susanne Wilde, Dolores J. Schendel. Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany

Abstract

2016

Neoantigen Summit 2016, Boston, USA

Targeting neoantigens by TCR therapy: Are we limited to treatment of tumors with highmutational loads and patients with pre-existing neoantigen-specific T cells? Dolores J. Schendel, CEO and CSO Medigene AG, Munich Germany

Abstract

ACCR – American Association for Cancer Research 2016, New Orleans, LA, USA

Tryggestad A., Axcrona K., Bigalke I., Inderberg-Suso, E., Skorstad, G., Axcrona U., Aamdal S., Gaudernack G., Schendel D., Lilleby W., Dueland S. and Kvalheim G. 2016. Clinical results of a Phase I/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivin. AACR, New Orleans, USA

Weitere Informationen

2015

ASH – American Society of Hematology Annual Meeting 2015, Orlando FL, USA

Bigalke I., Fløisand Y., Solum G., Hønnåshagen K., Lundby M., Anderson K., Sæbøe-Larssen S., Inderberg E., Eckl J., Schendel D., and Kvalheim G. 2015. AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome. ASH Orlando, USA.

Weitere Informationen

Phacilitate Immunotherapy Forum 2015, Washington DC, USA

Schendel D. 2014. Tailoring immunotherapies for patients with different stages of prostate cancer. Phacilitate Conference Washington DC, USA.

Abstract

2014

ASH – American Society of Hematology Annual Meeting 2014, San Francisco, USA

Bigalke I., Honnashagen K., Lundby M., Kasten J., Suso Inderberg E., Skoge L., Saboe-Larssen S., Schendel D., Kvalheim G. 2014. 2440 Vaccination with a New Generation of Fast Dendritic Cells Transfected with mRNA from hTERT, Survivin and Autologous Tumor Mount Strong Immune Responses and Prolong Survival. ASH San Francisco, USA.

Abstract

SITC – Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA

Schnorfeil F., Lichtenegger F., Geiger C., Köhnke T.,  Bücklein V., Altmann T., Wagner B., Henschler R., Bigalke I, Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2014. Next-generation dendritic cells for immunotherapy of acute myeloid leukemia. SITC National Harbor, USA.

Download PDF

SITC – Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA

Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Weis M., Longinotti G., Sailer N., Schendel D.J., Milošević S. 2014. Generation of tumor antigen specific CD4+ and CD8+ T cells by simultaneous MHC-I and –II epitope presentation in vitro and in vivo. SITC National Harbor, USA.

Download PDF

PIVAC – Progress in Vaccination Against Cancer 2014, Rom

Tryggestad A., Axcrona K., Bigalke I.,MInderberg-Suso E., Skorstad G, Axcrona U.,Steinar A., Gaudernack G.,Lilleby W., Dueland S., Kvalheim G. 2014. A PhaseI/II trial of adjuvant therapeutic vaccination in resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue,hTERT and survivin. PIVAC Rome, Italy.

Download PDF

Rampp I., Eichenlaub S., Römer I., Pohla H., Bigalke I., Sæbøe-Larssen S., Krackhardt A., Schendel D.J. Geiger C. 2014. Evaluation of a new generation dendritic cell-based vaccine for treatment of patients with castration-resistant prostate cancer. PIVAC Rome, Italy.

Download PDF

1st Immunotherapy of Cancer Conference 2014, München

Lichtenegger F., Beck B., Geiger C., Bigalke I., Kvalheim G., Hiddemann W., Schendel D., Subklewe M. 2014. Dendritic cell vaccination for postremission therapy in AML. ITOC Munich, Germany.

Download PDF

CIMT – Cancer Immunotherapy Annual Meeting 2014, Mainz

Tryggestad A.M.A., Bigalke I., Skorstad G., Skoge L.J., Honnashagen T.K., Axcrona K., Lilleby W., Kvalheim G. 2014. Cancer vaccines with hTERT and Survivin mRNA transfected fast DCs – a simplified and effective cancer vaccine. CIMT  Mainz, Germany.

Download PDF

Schnorfeil F.M., Lichtenegger F.S., Geiger C., Beck B., Koehnke T., Buecklein V., Altmann T., Wagner B., Henschler R., Bigalke I., Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2014. Next-generation dentritic cell vaccination as postremission therapy in AML. CIMT Mainz, Germany.

Download PDF

Rampp I.S., Eichenlaub S., Römer I., Pohla H., Bilgalke I., Saeboe-Larssen S., Schendel D.J., Geiger C. 2014. Development of a next generation  dentritic cell-based immunotherapie for patients with castration-resistant prostate cancer. CIMT Mainz, Germany.

Download PDF

Lorenz F.K.M., Wilde S., Voigt K., Kieback E., Schendel D.J., Uckert W. 2014. Gene optimization can generate cryptic epitopes that induce T cell responses. CIMT Mainz, Germany.

Download PDF

Bigalke I.,Honnashagen K., Lundby M., Kasten J., Inderberg Suso E.-M., Skoge L., Saboe-Larssen S., Schendel D.J., Kvalheim G. 2014. First clinical experience with a new generation of fast DCs transfected with mRNA from hTERT, survivin and autologous tumor. CIMT Mainz, Germany.

Download PDF

BioM seminar series 2014: m4-personalized medicine, München

Dr. Geiger C. 2014. A dendritic cell-based immunotherapy for patients with castration-resistant prostate cancer (CRPC). BioM Munich, Germany.

Download PDF

BioM forum 2014: Development and approval of ATMPs, München

Dr. Geiger C. 2014. “Dendritische Zellvakzine zur Behandlung minimaler residualer Krebserkrankungen – Discovery und Präklinik” (A dendritic cell vaccine for treatment of patients with minimal residual disease – discovery and pre-clinical development). BioM Munich, Germany.

Download PDF

Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Jahrestagung 2014, Hamburg 

Kobold S., Steffen J., Chaloupka M., Grassmann S., Henkel J., Castoldi R., Yi Zeng, Chmiliewski M., Schmollinger J., Schnurr M., Rothenfußer S., Schendel D.J., Abken H., Sustmann C, Niederfellner G., Klein C., Bourquin C., Endres S. 2014. Bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. DGHO Hamburg, Germany.

Download PDF

European Society for Blood and Marrow Transplantation Annual Meeting 2014, Mailand

von Luettichau I., Salat C., Wawer A.,  Noessner E.,  Eckl J.,  Multhoff G., Thiel U., Issels R.D., Kolb H.J., Burdach S. 2014. Targeting the Graft-Versus-Tumor Effect of DLI by Regional Hyperthermia to the Tumor Compartment. EBMT Milan, Italy.

Download PDF

2013

CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz

Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. Mai 2013. MHC Class-II Expression Targeting (CrossTAg) for the Generation of Tumor-Antigen-Specific CD4+ T Lymphocytes. CIMT Mainz, Germany.

Download PDF

CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz

Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S., 2013. Isolation of antigen-specific CD8+ T lymphocytes and molecular characterization of antigenic epitopes. CIMT Mainz, Germany.

Download PDF

SITC – Society for Immunotherapy of Cancer Annual Meeting 2013, National Harbor MD (USA)

Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. 2013. Induction and isolation of tumor antigen-specific CD4+ T lymphocytes using sorting signal directed MHC class-II expression. SITC National Harbor MD, USA.

Download PDF

Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S. 2013. Isolation of antigen-specific CD8+ T lymphocytes in vitro and in vivo. SITC National Harbor MD, USA.

Download PDF

Geiger C., Beck B., Bigalke I., Lichtenegger F.S., Heemskerk M., Saboe-Larssen S., Kvalheim G., Schendel D.J., Subklewe M. 2013. A new generation of dendritic cells optimized for the use in active immunotherapy – preclinical evaluation without an animal model. SITC National Harbor MD, USA.

Download PDF

Helmholtz Alliance 2013, Asselheim

Marin V., Longinotti G. 2013. Status of  GMP process development for TCR expression in lymphocytes. Helmholtz Alliance Asselheim, Germany.

Download PDF

Marin V., Longinotti G., Wieczorek A., Willde S., Mosetter B., Raffegerst S., Eckl J., Ellinger C., Frankenberger B., Leisegang M., Uckert W., Spranger S., Uharek L., Schendel D. 2013. Setting up of a GMP-compliant method for the production of human TCR-transduced T cells for the clinical testing. Helmholtz Alliance Asselheim, Germany.

Download PDF

 

Cellular Therapie International Symposium 2013, Erlangen  

Wilde S., Mosetter B., Wehner C., Ellinger C., Milosevic S., Frankenberger B., Schendel D. 2013. Isolation of NY-ESO-1-specific T cell receptors restricted by non-HLA-A*02:01 allotypes for TCR gene therapy. Cellular Therapie International Symposium Erlangen, Germany.

Download PDF

Cellular Therapie International Symposium 2013, Erlangen  

Geiger C., Beck B., Bigalke I., Lichtenegger F.S., Heemskerk M.,  Saboe-Larssen S., Kvalheim G., Schendel D.J., Subklewe M. 2013. A DC-based therapeutic vaccine for AML patients: preclinical evaluation of a new generation of DCs expressing the leukemia-associated antigens WT1 and PRAME. Cellular Therapie International Symposium Erlangen, Germany.

Download PDF

Tumor specific antigens derived from non-mutated non-coding regions of the genome can be targeted by T-cell receptor-transgenic T cells; Anna Schleicher, Alexandra Kuhlenkamp, Qingchuan Zhao, Krystel Vincent, Claude Perreault, Slavoljub Milosevic, Tiziana Franceschetti, and Daniel Sommermeyer

eTalk

ASH – American Society of Hematology Annual Meeting 2013, New Orleans LA (USA)

Lichtenegger F.S., Beck B., Geiger C., Munker D., Schlueter M., Draenert R., Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2013. Improving Efficacy of Dendritic Cell Vaccination in AML: Optimization of the DC Generation Protocol and Maximization of T Cell Responses by Immune Checkpoint Blockade. ASH New Orleans LA, USA.

Download PDF

Keystone Symposia 2013, USA

Smith S., Sommermeyer D.,  Schmitt T.,  Schendel D.J., Bernhard H., Piepenbrink K., Baker B., Blankenstein T., Uckert W., Greenberg P., Kranz D. 2013. Engineering high-affinity human single-chain T cell receptors against cancer antigens. Keystone Symposia, USA.

Download PDF

Acute Leukemias XIV, International Symposium 2013, München 

PD Dr. Subklewe M. 2013. Dendritic Cell Vaccination for Postremission Therapy in AML. Acute Leukemias XIV München, Germany.

Download PDF

European Society for Blood and Marrow Transplantation Annual Meeting 2013, London (UK)

Wieczorek A., Marin V., Raffegerst S., Wilde S., Mosetter B ., Spranger S., Frankenberger B., Leisegang M., Uckert W., Uharek L., Schendel D.J. 2013. HMMR-redirected adoptive T cell therapy for treatment of refractory acute myeloid leukemia in context of mismatched stem cell transplantation. EBMT London, UK.

Download PDF

2012

SFB TR 36 Annual Meeting 2012 Berlin

Wilde S., Sommermeyer D., Leisegang M., Frankenberger B., Mosetter B., Uckert W., Schendel D.J. 2012. Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition. SFB TR 36 Berlin, Germany.

Download PDF